Tailored Treatment for Hepatitis C
- 31 August 2008
- journal article
- research article
- Published by Elsevier in Clinics in Liver Disease
- Vol. 12 (3) , 507-528
- https://doi.org/10.1016/j.cld.2008.03.011
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow respondersHepatology, 2007
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trialHepatology, 2006
- 8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’Journal of Hepatology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- A 48‐Week Duration of Therapy with Pegylated Interferon α2b plus Ribavirin May Be Too Short to Maximize Long‐Term Response among Patients Infected with Genotype‐1 Hepatitis C VirusThe Journal of Infectious Diseases, 2004
- Extending Combination Therapy With Peginterferon Alfa–2B Plus Ribavirin for Genotype 1 Chronic Hepatitis C Late Responders: A Report of 9 CasesHepatology, 2003